Blog

Health care concept. Business hand holding virtual medical health care icons with medical network connection.

HealthTech leverages a convergence of hardware, software, apps, devices, and AI to drive behaviour change and significantly improve patient outcomes, especially in managing chronic conditions and promoting wellness.Here is a breakdown of the role of each component:1. Hardware and Devices Wearable Devices (e.g., smartwatches, fitness trackers): Collect real-time physiological and activity data (steps, heart rate, sleep, blood oxygen).Behaviour Change Mechanism: Self-monitoring and feedback motivate users to increase physical activity, improve sleep hygiene, or manage stress. IoT (Internet of Things) Medical Devices (e.g., smart glucose monitors, connected inhalers): Automate data collection for specific health metrics.Behaviour Change Mechanism: Simplify adherence by making tracking automatic and providing time-based cues (reminders to use the device). Telehealth/Remote Patient Monitoring (RPM) Equipment: Allow remote consultation and data transmission.Behaviour Change Mechanism: Increase access to care and support, removing logistical barriers to follow-up and enabling real-time professional coaching. 2. Software and Apps Mobile Health (mHealth) Apps: Provide structured programs, personalized goals, and educational content.Behaviour Change Mechanism: Offer goal setting, progress tracking, and positive reinforcement (e.g., virtual rewards, badges) to encourage habit formation (e.g., for diet, exercise, or medication adherence). Patient Portals/Electronic Health Records (EHRs): Give patients access to their health data, appointment schedules, and lab results.Behaviour Change Mechanism: Empowerment and education, allowing patients to be active participants in their care and make informed decisions. 3. Artificial Intelligence (AI) Personalisation and Recommendation Engines: Analyze large datasets from devices and apps to tailor interventions.Behaviour Change Mechanism: Deliver hyper-personalized nudges and recommendations (e.g., "Take a 15-minute walk at 3 PM, as you're usually inactive then") which are more effective than generic advice. This improves autonomy support. AI-Powered Chatbots and Virtual Coaches: Provide accessible, non-judgmental, conversational support and health coaching.Behaviour Change Mechanism: Offer real-time support and implement behavioral science principles (like Cognitive Behavioral Therapy - CBT) at scale to help users manage conditions like anxiety, depression, or chronic diseases. They can provide timely prompts for things like medication or mental check-ins. Predictive Analytics: Identify patients at high risk of non-adherence or adverse events.Improve Outcomes: Allow clinicians or automated systems to perform proactive outreach before a problem occurs, fundamentally changing the patient's course of action. &nbsp;Overall Impact on Patient Outcomes: By blending these technologies, healthtech systems can:Enhance Adherence: Simplify and automate routines (e.g., medication reminders, exercise tracking) to help patients stick to treatment plans. Increase Engagement: Use gamification, personalized feedback, and social support to make managing health more rewarding and less burdensome. Provide Continuous Support: Move healthcare beyond the clinic visit, offering 24/7 coaching and monitoring. Improve Data Quality: Provide objective, real-world data to patients and providers, leading to better diagnostic and treatment decisions. Scale Interventions: Deliver effective, personalized behaviour change programs to large populations cost-effectively.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title=" lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary"> lloyd@nelsonadvisors.co.uk</a>

Hardware, Software, Apps, Devices, AI : HealthTech driving Behaviour Change to improve Patient Outcomes

The first half of 2025 has established a clear trajectory for the UK and broader European HealthTech M&amp;A markets. The European digital health funding landscape, in particular, saw an impressive 52% year-on-year increase in the first half of the year, reaching $3.4 Billion across 182 deals. This performance is particularly noteworthy because it runs contrary to the global digital health funding trend, which experienced a 13% year-on-year decline over the same period. The UK's HealthTech sector has been a key contributor to this regional strength, with the UK MedTech market alone projected to reach £15.7 Billion in 2025, and a steady growth forecast to £20.5 Billion by 2030. &nbsp;&nbsp; Overall, deal volume for HealthTech M&amp;A is on pace to exceed 2024's total. In the first half of 2025, there were 277 deals in HealthTech, which projects a full-year total well above the 467 deals recorded in 2024.Similarly, disclosed deal value is on a growth path, reaching $10.3 Billion in H1 2025, on pace to surpass the 2024 total of $19.2 Billion. However, it is important to note that only a small fraction (11%) of transactions disclose deal values, suggesting the actual value is significantly higher. &nbsp;&nbsp; The resilience of this market is largely attributed to a concentration of capital in fewer but larger transactions. The first half of the year saw four mega deals of over $1 Billion globally. In Europe, a handful of large "mega-deals" valued at $100 Million or more drove a significant portion of the total venture capital investment, with seven such deals accounting for 56% of the region's total investment. This trend signifies a shift away from a "spray and pray" approach towards a more selective and strategic model of "high-conviction investment". &nbsp;&nbsp; The divergence between the European mar<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">ket's performance and the global trend is a key indicator of the UK's unique value proposition. The UK's </a>strong innovation capacity, supported by a clear governmental commitment to digital transformation, provides a more stable and predictable environment for scaling HealthTech solutions compared to other regions.&nbsp; &nbsp;&nbsp; The NHS's long-term strategic plans and substantial investment create a powerful market signal and a ready customer base, which reduces regulatory uncertainty and makes the region a highly attractive destination for capital. This institutional demand and strategic clarity serve as a significant tailwind that helps to insulate the UK HealthTech sector from broader global macroeconomic pressures.Full report availabe at <a data-mce-href="https://www.healthcare.digital/single-post/uk-healthtech-m-a-market-what-s-hot-and-what-s-not-in-2025-and-looking-ahead-into-2026" href="https://www.healthcare.digital/single-post/uk-healthtech-m-a-market-what-s-hot-and-what-s-not-in-2025-and-looking-ahead-into-2026" title="https://www.healthcare.digital/single-post/uk-healthtech-m-a-market-what-s-hot-and-what-s-not-in-2025-and-looking-ahead-into-2026" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/uk-healthtech-m-a-market-what-s-hot-and-what-s-not-in-2025-and-looking-ahead-into-2026</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

The 2025 UK HealthTech M&A Landscape: A Cautious but Resilient Rebound

The UK National Commission on the Regulation of AI in Healthcare has been established as a critical, non-statutory advisory body by the Medicines and Healthcare products Regulatory Agency (MHRA) to address the growing disparity between the rapid pace of artificial intelligence (AI) innovation and a legacy regulatory framework. Its mandate is to review existing regulations and provide a comprehensive set of recommendations for a new, rewritten rulebook for AI in healthcare, which is expected to be published next year. This strategic initiative is designed with a dual purpose: to accelerate the safe and effective adoption of cutting-edge AI tools within the National Health Service (NHS) and to position the UK as a global leader in responsible health technology regulation, thereby attracting significant international investment. &nbsp;&nbsp; The Commission's work is not merely a bureaucratic exercise; it is a direct response to a series of foundational challenges unique to AI. These include the "black box" problem, which erodes trust and complicates accountability; algorithmic bias, which can perpetuate and amplify existing health inequalities; and the difficulty of regulating continuously learning, or adaptive, AI systems that evolve after they are deployed.&nbsp; While the MHRA has already begun addressing these issues through initiatives like the AI Airlock sandbox and various change programmes, the Commission's role is to formalise these efforts into a coherent, national framework.&nbsp; The analysis further reveals that the success of this regulatory reform will depend on addressing broader systemic barriers to adoption, such as fragmented IT systems, complex procurement processes, and a general lack of AI literacy within the NHS workforce. By tackling both the regulatory and operational hurdles, the UK aims to build a comprehensive ecosystem that fosters innovation, ensures patient safety, and delivers tangible benefits for the health service. Source: <a data-mce-href="https://www.gov.uk/government/groups/national-commission-into-the-regulation-of-ai-in-healthcare" href="https://www.gov.uk/government/groups/national-commission-into-the-regulation-of-ai-in-healthcare" title="https://www.gov.uk/government/groups/national-commission-into-the-regulation-of-ai-in-healthcare" target="_blank" rel="noopener">https://www.gov.uk/government/groups/national-commission-into-the-regulation-of-ai-in-healthcare</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email l<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">loyd@nelsonadvisors.co.uk</a>

The UK National Commission on the Regulation of AI in Healthcare

The recurring problem in healthtech around defining Annual Recurring Revenue (ARR) stems from the complexities of the healthcare revenue cycle and the diversity of business models, which often go beyond the simple subscription model of traditional SaaS.While the general definition of ARR is the predictable, recurring revenue a company expects to receive annually from its customers, healthtech companies face specific challenges:1. Hybrid Business Models Many healthtech companies are not pure Software-as-a-Service (SaaS). They are often Tech-Enabled Services or a hybrid, where recurring revenue is tied to:&nbsp; Usage or Consumption: Revenue based on the volume of transactions, claims processed, or per-patient engagement, which can fluctuate and be less predictable than a flat subscription. Capitation/Per Member Per Month (PMPM) Fees: Payments received from payers (insurers) or employers on a per-member basis, which may have variable enrollment or utilization rates. Service Components: Blending software subscriptions with professional services (e.g., clinical support, implementation, data analytics), where only the truly recurring software/platform fee should be counted as ARR. The Problem: Distinguishing between truly recurring revenue (ARR) and variable or one-time service revenue can be difficult. Misclassifying these can artificially inflate the ARR figure, misleading investors about the company's financial health and predictability.2. Implementation and One-Time Fees Healthtech deals, especially with large hospital systems or payers, often include significant one-time fees for:Implementation/Integration: Connecting the tech solution to Electronic Health Records (EHRs) and other legacy systems. Customisation: Tailoring the platform to specific clinical or administrative workflows.The Problem: These one-time fees can be large and make up a significant portion of the initial contract value. Including them in ARR is a common mistake, as they do not recur annually. ARR must strictly exclude these non-recurring charges.3. Long Sales Cycles and Contract Lag Healthcare sales cycles are notoriously long, and contracts often include phased rollouts or terms that delay the start of paid subscription usage.The Problem: There can be a significant lag between signing a contract and the revenue "going live." This creates a distinction between:Committed ARR (CARR): The total value of recurring revenue that has been contractually signed but not yet fully realized or live. Realised ARR: The revenue that is currently being collected based on active users or members.&nbsp; &nbsp; For accurate forecasting and reporting, companies must clearly delineate between these two, as investors prioritise the predictable, realized revenue stream.4. Regulatory and Payment Complexity Unlike generic SaaS, healthtech revenue is highly dependent on complex regulations (like HIPAA) and the intricate healthcare payment landscape (payers, providers, patients).The Problem: Revenue can be subject to:Prior Authorizations and Denials: Technology that helps with the revenue cycle (RCM) may have a recurring fee tied to success metrics, which are influenced by external denial rates.Reimbursement Changes: New billing codes or payer policies can instantly impact the value of a tech solution, making the "annual" value of the recurring fee less stable.In short, the problem is defining a clear, clean, and consistent metric for predictable annual revenue when the core business models and revenue streams are inherently complex, service-heavy, and influenced by external regulatory and payment factors unique to the healthcare industry.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

HealthTech's Recurring Problem: How to define Annually Recurring Revenue

Professional handshake signifying agreement between business professionals during an office meeting focused on collaboration and teamwork

For healthtech founders, understanding the bridge from Enterprise Value (EV) to Equity Value is critical for M&amp;A. While a buyer's offer is typically based on a company's EV, the value of its operating business, the actual cash you receive as a founder is based on its Equity Value. The bridge is a simple calculation that adjusts the EV for your company's balance sheet to determine the final payment to shareholders.The Core Formula 💰 The foundational formula for the EV-to-Equity Value bridge is:Equity Value = Enterprise Value - Net Debt + Other AdjustmentsLet's break down the key components:Enterprise Value (EV): This is the headline number in an M&amp;A offer. It represents the value of your company's core operations, independent of how it's financed. It's what the buyer is paying for your business itself. In healthtech, EV is often calculated using a multiple of your revenue or EBITDA (e.g., EV = Revenue x 5x). Equity Value: This is the final value attributable to shareholders. It is the amount of cash you, your co-founders, and investors will receive at closing. &nbsp; &nbsp;The Bridge: A Closer Look 🌉 The difference between EV and Equity Value is a function of a company's balance sheet. The buyer typically wants to acquire your operating business "cash-free, debt-free," meaning they aren't paying for your cash on hand and won't be inheriting your debt.Net Debt: This is the most significant adjustment. It represents your company's total debt minus its cash and cash equivalents.Formula: Net Debt = Total Debt - Cash &amp; Cash Equivalents Impact: Any debt on your balance sheet will reduce the final Equity Value. Conversely, any cash on hand will increase it, as it's typically distributed to shareholders. Healthtech Context: Be sure to include all debt-like items, which might be less obvious in a tech company, such as capital leases, unfunded pension liabilities, or deferred revenue that is treated as a liability in the deal structure. Other Adjustments: In a real-world M&amp;A deal, other balance sheet items can impact the final price. These are often negotiated and will depend on the deal's specific terms.Preferred Stock: Any value owed to preferred stockholders (e.g., from a Series A or B round) is subtracted from the EV. The proceeds from the sale are distributed according to a pre-defined waterfall, with preferred shareholders often getting paid before common shareholders. Working Capital Adjustments: Buyers will often set a target for a company's working capital (current assets minus current liabilities). If your working capital at closing is below the target, the purchase price may be reduced. If it's above, it may be increased. Transaction Costs: Legal, investment banking, and accounting fees related to the deal are typically paid out of the proceeds, reducing the final amount distributed to shareholders. &nbsp; An Example for a Healthtech Startup 🏥 Let's imagine your digital health company, "HealthMetrics," has received an offer.Proposed Enterprise Value (EV): $50 million (based on a 5x multiple of your $10M in ARR) Now, let's look at your balance sheet to calculate the final Equity Value.Cash on hand: $3 million Total Debt: $5 million (e.g., a bank loan for equipment) Preferred Stock: $8 million (the liquidation preference for your investors) Working Capital Adjustment: Let's assume a negotiated negative adjustment of $500,000. Transaction Costs: $1.5 million The Bridge Calculation:Start with EV: $50,000,000 Subtract Total Debt: - $5,000,000 Add Cash: + $3,000,000 Subtract Preferred Stock: - $8,000,000 Subtract Working Capital Adjustment: - $500,000 Subtract Transaction Costs: - $1,500,000 Final Equity Value = $33,000,000Key Takeaway: The "cheat sheet" is to remember that the EV is not the cash you'll walk away with. You must account for all financial obligations and adjustments to bridge from the EV to the final Equity Value that is paid out to you and your investors.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Enterprise Value to Equity Value bridge explained for Healthtech Founders

Businessman analyzes the graph of trend market growth in 2025 and plans business growth and profit increase in the year 2025. plan finances of the business

In healthtech M&amp;A in 2025, earn-outs are increasingly common and are being used to bridge valuation gaps between buyers and sellers, mitigate risk, and align incentives. The use of these structures is particularly prevalent for high-growth, early-stage companies and those with unproven or developing technologies, such as AI-driven platforms and digital therapeutics.&nbsp;Key Trends and Structures 🤝 Risk-Sharing Mechanism: Earn-outs are a way for buyers to manage the risk of overpaying for a company with unproven technology or an uncertain future revenue stream. They allow the buyer to pay a lower upfront price and a contingent, future payment if the business hits agreed-upon performance metrics. Contingent on Performance: Payments are tied to specific, measurable milestones. These milestones can be financial, like achieving a certain revenue or adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), or non-financial, such as receiving regulatory approval (e.g., FDA clearance), launching a new product, or hitting specific customer acquisition targets. Typical Metrics: While revenue and adjusted EBITDA are standard, healthtech deals often incorporate milestone-driven metrics due to the nature of the industry. This is particularly true for biopharma and diagnostics companies, where a deal might be structured with an initial payment and an earn-out tied to a clinical trial's success, regulatory approval, or a product's commercial launch. Earn-out Period and Percentage: Earn-out periods typically range from one to three years to allow sufficient time for the acquired company to achieve the agreed-upon milestones. The contingent portion of the total deal value can vary widely, but for a seller's business that is already generating revenue, the earn-out may constitute 10-20% of the total purchase price. Market Dynamics in 2025 📈 The healthtech M&amp;A market in 2025 is driven by several factors, which influence the use and structure of earn-outs:AI Integration: Companies with proprietary AI algorithms and scalable platforms are commanding higher valuations, often seeing multiples of 6-8x revenue, above the sector average of 4-6x. Earn-outs are used to justify these premiums by tying a portion of the valuation to the successful commercialization and integration of the AI technology. Regulatory Evolution: As regulatory bodies like the FDA refine their frameworks for digital health tools, clear regulatory pathways boost buyer confidence. However, for companies still navigating this uncertainty, earn-outs are a crucial tool to manage risk, with payments contingent on achieving regulatory milestones. Shift to Value-Based Care: Buyers are increasingly interested in healthtech that delivers measurable cost savings and improved patient outcomes. Companies with platforms enabling this shift (e.g., remote monitoring, population health analytics) attract a premium, and earn-outs are used to ensure the technology delivers on its promised value.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Hardware, Software, Apps, Devices, AI : HealthTech drivin...

The 2025 UK HealthTech M&A Landscape: A Cautious but Resi...

The UK National Commission on the Regulation of AI in Hea...

HealthTech's Recurring Problem: How to define Annually Re...

Enterprise Value to Equity Value bridge explained for Hea...

HealthTech M&A Earn Outs: Key Trends, Structures and Mark...